Browse companies
/
InSilico Medicine
InSilico Medicine stock
InSilico Medicine went public on December 30, 2025. This company is no longer tradable on Hiive.
$35.00
IPO price
$29.98
Day 1 closing price
Source: Hiive
LEGEND
All data points are in price per share (PPS)
Invest in pre-IPO companies
High-growth private companies trade on Hiive before they go public. Sign up to explore the market.
InSilico Medicine IPO
InSilico Medicine completed its IPO on December 30, 2025, listing with the ticker 03696.HK. Cerebras Systems is no longer tradable on Hiive.
Final Hiive Price
If you have any questions about buying or selling shares of private companies, don't hesitate to contact us at [email protected].
About InSilico Medicine
Researcher and developer of an artificial intelligence (AI) platform and new drugs designed to deliver breakthrough solutions for cancer, fibrosis, immunity, central nervous system diseases and age-related diseases.
Last private funding round
DATE
Capital Raised
$110m of $536.30m total
INDUSTRIES
Health Care
Pharmaceutical
Artificial Intelligence
Biotechnology
Note: Information is provided for informational and educational purposes only, and is not a recommendation to buy or sell securities. It is an approximation, based on publicly available data and information from third-party sources. Hiive has not verified them as accurate, complete, or up-to-date. There may be material, non-public information that impacts valuation, and which is unavailable to Hiive or to you. Before you make any investments, you should verify any information that is important to your investment decision, and conduct your own assessment and analysis.
Invest in pre-IPO companies
High-growth private companies trade on Hiive before they go public. Sign up to explore the market.
Sign upInSilico Medicine IPO
InSilico Medicine completed its IPO on December 30, 2025, listing with the ticker 03696.HK. Cerebras Systems is no longer tradable on Hiive.
Final Hiive Price:
If you have any questions about buying or selling shares of private companies, don't hesitate to contact us at [email protected].
FAQ
How to invest in InSilico Medicine?
InSilico Medicine is a publicly traded company under the stock ticker 03696.HK. To invest, you must open a brokerage account with a platform that allows you to buy U.S. stocks, such as Robinhood, Vanguard, Fidelity, or your bank's brokerage division. Once your account is funded, search for 03696.HK stock and place a buy order.
Can you buy InSilico Medicine stock?
Since InSilico Medicine has gone public via IPO (initial public offering), SPAC, or direct listing, its shares are available to all individual investors in the public market. You can purchase shares using the InSilico Medicine stock ticker symbol 03696.HK through any standard brokerage account.
Can you sell InSilico Medicine shares before it goes public?
You can freely sell InSilico Medicine stock after its IPO (initial public offering), SPAC, or direct listing, provided you purchased the shares on the open market through your brokerage account. Certain early investors, employees, and company executives are often subject to a lock-up period after the company trades publicly which restricts them from selling their shares for a set time — typically 90 to 180 days. Once that lock-up period expires, those shareholders will also be able to sell their InSilico Medicine shares without restriction.
What is InSilico Medicine's stock price?
To find the current stock price for InSilico Medicine, you first need its stock ticker symbol. You can find this information by searching the company name on major financial websites or by checking the investor relations section of the company's official website. Once you have the ticker 03696.HK for InSilico Medicine, enter it into any brokerage account platform or reputable financial news site to see its real-time share price.
What is the valuation of InSilico Medicine?
InSilico Medicine's valuation is primarily measured by its market capitalization, which constantly changes with its stock price. This figure is calculated by multiplying the live share price by the total number of outstanding shares, reflecting its public market value. Investors also look at metrics like the enterprise value and price-to-sales ratio to assess the premium the market places on InSilico Medicine.
Is InSilico Medicine publicly traded?
Yes, InSilico Medicine is publicly traded and its stock is available for purchase by the general public. The company completed its IPO (initial public offering), SPAC, or direct listing, and its shares are now listed publicly. Investors can find and trade the shares under the stock 03696.HK through any standard brokerage account.
Trade private stock now.
Securities are offered by Hiive Markets Limited, member of FINRA / SIPC and registered exempt market dealer in Ontario, British Columbia, Alberta, Saskatchewan, Manitoba and Nova Scotia. Brokerage fees may apply. Find Hiive on BrokerCheck. Hiive does not conduct or solicit brokerage activities in any jurisdiction where it is not registered or otherwise authorized to do so.
The information on this website is provided “as-is”, some of which may originate from third-party sources. Hiive has not verified these sources as accurate, complete, or up to date. Investing in private securities is speculative, illiquid, and involves the risk of loss. Pre-IPO companies are privately owned; not all private companies will experience an IPO or other liquidity event. Hiive does not provide investment, financial, legal, or tax advice, and Hiive customers should obtain independent advice prior to buying or selling on Hiive. References to securities do not constitute an offer to buy or sell, a solicitation of an offer, nor a recommendation to buy or sell any security. Hiive is not affiliated or associated with, or endorsed by, any of the companies mentioned herein. All services or trademarks are the property of their respective owners.
© The Hiive Company Limited 2026. All rights reserved. By using this site, you accept our Terms of Use, Security and Privacy Policy. Before engaging with this broker-dealer, review these important Disclosures and the Form CRS (US) and Relationship Disclosure (Canada).
